Drug intelligence / Profile preview

TPC-020

Development stage: Preclinical
Lead developer: Tetra Pharm Technologies
Modality: Small Molecules

Overview

TPC-020 is an investigational small molecule drug candidate being developed by Tetra Pharm Technologies for the treatment of Parkinson's Disease. Currently in the discovery and pre-clinical stages, TPC-020 is part of a pipeline focused on modulating the endocannabinoid system (ECS) to treat neurological and psychiatric disorders. Tetra Pharm Technologies utilizes proprietary formulation and delivery technologies to optimize the therapeutic potential of cannabinoid-derived compounds. While the specific molecular target of TPC-020 within the ECS has not been disclosed, the program aims to leverage the neuroprotective and symptomatic benefits associated with cannabinoid receptor modulation in neurodegenerative pathologies.

Beyond the preview

Go deeper on TPC-020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPC-020.

Explore the full profile